AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma?
However, even with encouraging efficacy data, penetrating the Hodgkin lymphoma market is challenging.
Immuno
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth
ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
Asbestos-related cancers still prevalent in the UK
GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
Implementing pragmatic approaches for the patients and sites in oncology trials
